The mechanisms regulating KMT2D expression and its downstream effects in pancreatic tumorigenesis represent a potential therapeutic approach to pancreatic cancer as an epigenome-regulated metabolic disease64. This evidence concerns the gene KMT2D and familial pancreatic carcinoma.